Bioprosthetic valve durability: TAVR versus SAVR using different definitions of valve deterioration

Transcatheter aortic valve replacement (TAVR) has become the treatment of choice for patients with symptomatic severe aortic stenosis who are at high or extreme risk for surgical aortic valve replacement (SAVR) [1,2]. Two landmark randomised trials have recently reported data supporting the use of TAVR in intermediate surgical risk patients [3,4]. Newer generations of transcatheter valve design and optimization of patient selection, procedural planning and technique have driven continued improvements in efficacy and reduction in complication rates.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research